Longevity without grant funding
As part of the Wellcome Sanger Institute, COSMIC has become an integral part of the cancer community. As the world’s most comprehensive Knowledgebase for somatic mutations in human cancers, the far-reaching impact of COSMIC's expertly curated data spans industry, healthcare and research.
To ensure a future where we can continue to support the evolving needs of the cancer community, we developed a sustainable growth model in 2015. Under this model, commercial use requires the purchase of a licence. This allows us to remain a reliable resource while staying committed to our support of the academic community.
A commercial distribution partnership
COSMIC actively sought a partnership with industry to help scale its capabilities. In January 2021, COSMIC entered into a commercial distribution partnership with QIAGEN Digital Insights (QDI), enabling COSMIC to ensure global accessibility to our valuable knowledgebase. Under this agreement, all commercial licensing enquiries are handled by the QIAGEN sales team.
QIAGEN Digital Insights is a Business Unit with QIAGEN N.V., a Netherlands-based holding company and a leading global life science solutions provider. QIAGEN Digital Insights delivers expert curated genomic and clinical knowledge, software and services for scientists and clinicians to improve insights, accelerate decision and deliver better outcomes.
QIAGEN leverages its experienced software sales team and global customer network to grow the adoption and utilisation of the COSMIC Database. Both Sanger and QIAGEN share the same philosophy to ensure high quality knowledge access through carefully curated, compiled and standardised information.
